Keystone Symposia

Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2015


Here are the related meetings in 2020:
Antibodies as Drugs: From B Cell Biology to New Treatments (B1)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antibodies as Drugs: Immunological Scaffolds as Therapeutics (J8)


Organizer(s) Pablo Umaña, Mark X. Sliwkowski and Martin J. Glennie
February 8—13, 2015
Fairmont Banff Springs • Banff, AB Canada
Discounted Abstract Deadline: Oct 9, 2014
Abstract Deadline: Nov 12, 2014
Scholarship Deadline: Oct 9, 2014
Discounted Registration Deadline: Dec 9, 2014

Sponsored by Genentech, Inc., ImmunoGen, Inc., Mersana Therapeutics, OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Shire Human Genetic Therapies


Summary of Meeting:
Monoclonal antibodies are now an established class of drugs in oncology and inflammation. In addition, exciting progress has been recently made on next-generation, engineered therapeutic antibodies and alternative immunological scaffolds, with the first examples from this class being recently approved by the FDA and EMA. This Keystone Symposia meeting will review progress in this area, including lessons learned in the clinic and how this can be applied to new targets and drug candidates. The meeting will cover major areas of activity including: 1) Increasing antibody potency via antibody engineering, better engaging immune effector cells, and improvements in targeted delivery of effectors via fusion proteins and via conjugation of cytotoxic drugs; 2) Applying alternative targeting approaches to increase the therapeutic window, such as pre-targeting and site-specific antibody unmasking; 3) Novel antibodies in areas outside of oncology, including infectious diseases, neurology and chronic inflammation; 4) Engineering antibodies and scaffolds for alternative delivery routes and improved disposition; 5) Clinical progress with multi-specific antibodies; and 6) Recent advances in (i) addressing difficult targets such as GPCRs and ion channels, (ii) alternative immunological scaffolds, and (iii) novel antibody library technologies. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on “Tumor Immunology - Multidisciplinary Science Driving Combination Therapy,” which will be co-located with this meeting.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


SUNDAY, FEBRUARY 8

4:00—8:00 PM
Arrival and Registration

Van Horne Foyer
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Van Horne Foyer

MONDAY, FEBRUARY 9

7:00—8:00 AM
Breakfast

Mezzanine 2
8:00—9:00 AM
Keynote Address

Van Horne Ballroom C
Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Antibodies Blocking the PD-1 Pathway: A New Age for Cancer Therapy

8:00—9:30 AM
Keynote Session

Van Horne Ballroom A/B
Axel Hoos, GlaxoSmithKline, USA
Combination Therapies – Immunology Meets Oncology

Robert D. Schreiber, Washington University School of Medicine, USA
Using Genomics Approaches to Inform Cancer Immunotherapy

9:00—11:30 AM
Antibody Drug Conjugates in the Clinic

Van Horne Ballroom C
* Peter D. Senter, Seattle Genetics Inc., USA
Potent Antibody-Based Conjugates for Cancer Therapy: From Early-Stage Research to a Clinically Approved Drug

William C. Olson, Regeneron Pharmaceuticals, Inc., USA
Clinical-Stage ADCs: What's Trending Amongst this 50ish Crowd

Joseph J. Bellucci, Duke University, USA
Short Talk: A Non-Canonical Function of Sortase Enables Conjugation of Small Molecules to Lysine Residues in Proteins

Philipp Müller, University Hospital Basel, Switzerland
Short Talk: The Antibody-Drug-Conjugate T-DM1 Induces Potent Anti-Tumor Immunity in HER2+ Breast Cancer: Implications for Combinations with Immunotherapy

Sabine Imhof-Jung, Roche Innovation Center Penzberg, Germany
Clinical Progress with Anti-Cancer Cytolytic Fusion Proteins

9:30—11:45 AM
Inflammation and the Dynamics of the Tumor Microenvironment

Van Horne Ballroom A/B
Robert Peter Gale, Hammersmith and Celgene, USA
The Diversity of Myeloid Cell Populations Driving Carcinogenesis

Amy-Jo Casbon, Amgen, USA
Short Talk: Tumors Reprogram Early Myeloid Differentiation in the Bone Marrow to Generate Immunosuppressive Neutrophils

Guido Kroemer, Cordeliers Research Center, France
How Chemotherapeutics Start an Intratumoral Anticancer Immune Response

* Elizabeth M. Jaffee, Johns Hopkins University, USA
Combinatorial Immunotherapies with the Potential to Reverse the Carcinogenesis Process

Natasa Obermajer, University of Pittsburgh, USA
Short Talk: Th17 into Treg Cell Conversion: A Novel Pathway of Treg Cell Emergence

9:40—10:00 AM
Coffee Break

Van Horne Foyer
11:30 AM—1:00 PM
Poster Setup

Mezzanine 2
1:00—10:00 PM
Poster Viewing

Mezzanine 2
11:30 AM—2:30 PM
On Own for Lunch

2:30—4:30 PM
Workshop 1: Novel Scaffolds

Van Horne Ballroom C
* Pablo Umaña, Roche Innovation Center Zürich, Switzerland

* Michael Stumpp, Molecular Partners, Switzerland

David P. Chimento, Rockland Immunochemicals, Inc., USA
Differential Affinity Single Domain Antibodies: Novel Agents for in vivo Imaging and Targeted Therapies

Birgit Dreier, University of Zürich, Switzerland
Generic Adenovirus Delivery System Using Bispecific DARPin-Based Adapters

Kyle Landgraf, AvidBiotics Corp., USA
Engineering Human MICA as a Novel Immunotherapeutic Scaffold

Tao Dao, Memorial Sloan Kettering, USA
Potent Therapeutic Activity of a TCR-Mimic Bi-Specific T Cell Engager Antibody against Human Cancers Expressing WT1 in the Context of HLA-A02

Johan Nilvebrant, Royal Institute of Technology, Sweden
ADAPT - A Novel Scaffold Protein for Radionuclide Molecular Imaging

Sabrina Oliveira, Utrecht University, Netherlands
Nanobody-Photosensitizer Conjugates as an Alternative Format for Targeted Photodynamic Therapy

2:30—4:30 PM
Workshop 1: Integration of Science through Collaboration - New Models

Van Horne Ballroom A/B
* Axel Hoos, GlaxoSmithKline, USA

* Ira Mellman, Genentech, Inc., USA

* Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA

* Elizabeth M. Jaffee, Johns Hopkins University, USA

Arthur Machlenkin, Pantheon Biosciences Ltd, Israel
Identification of Novel Immuno-Modulatory Targets for Cancer Immunotherapy

Bruce Freimark, Pulse Biosciences, USA
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid-Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment

Marit Martha van Buuren, Neon Therapeutics, USA
Intratumoral CD4+ T Cell Reactivity Against Mutated Antigens Is Commonly Observed in Human Melanoma

Francisca Wollerton, F-star, UK
Modular Antibody TechnologyTM Platform Delivers Molecules of Diverse Formats and Biology

Jennie R. Lill, Genentech, Inc., USA
Mass-Spectrometry Based Characterization of the MHC-I Peptide Repertoire in Response to Drug Treatment

4:30—5:00 PM
Coffee Available

Van Horne Foyer
5:00—7:00 PM
Antibody-Targeted Fusion Proteins for Cancer Therapy

Van Horne Ballroom C
Mark X. Sliwkowski, Genentech, Inc., USA
Antibody Therapeutics in the Treatment of HER2-Positive Cancer: Past, Present and Future

Sherie L. Morrison, University of California, Los Angeles, USA
Antibody Fusions with Interferon for the Treatment of Malignancy

* Tibor P. Keler, Celldex Therapeutics, Inc., USA
DC-Targeted Antibody Fusions as Cancer Vaccines

Christian Klein, Roche, Switzerland
Short Talk: CEA-Targeted IL-2 Variant (IL2v)-Based Immunocytokine for Immunotherapy of Cancer

5:00—7:15 PM
Genetics and Epigenetics of the Immune System

Van Horne Ballroom A/B
Tak W. Mak, Campbell Family Institute for Breast Cancer, Canada
Genetic and Epigenetic Alterations that Drive Neoantigen Development

Morten Frier Gjerstorff, University of Southern Denmark, Denmark
Short Talk: Oncogenic Functions of Cancer/Testis Antigen SSX2 Highlight its Therapeutic Potential

* Laurence Zitvogel, Institut Gustave Roussy, France
Gut Microbiota and Anticancer Immune Responses

Eduardo M. Sotomayor, Moffitt Cancer Center and Research Institute, USA
Combinatorial Approaches that Integrate Epigenetic Therapy with Immunotherapy

Brian H. Ladle, Johns Hopkins University, USA
Short Talk: De novo DNA Methylation by DNMT3a Controls CD8+ T Cell Fate Decisions following Activation

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
7:30—10:00 PM
Poster Session 1

Mezzanine 2

TUESDAY, FEBRUARY 10

7:00—8:00 AM
Breakfast

Mezzanine 2
8:00—11:15 AM
Antibodies for Cancer Immunotherapy

Van Horne Ballroom C
Alan J. Korman, Bristol-Myers Squibb, USA
Anti-Tumor Activity of Immunomodulatory Antibodies

* Martin J. Glennie, University of Southampton, UK
Agonistic Antibodies Targeting Costimulatory Receptors

* Pablo Umaña, Roche Innovation Center Zürich, Switzerland
Enhancing Immune Effector Functions: Gazyva and Beyond

Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Clinical Progress with T Cell-Engaging Bispecific Antibodies

Elizabeth E. Evans, Vaccinex, Inc., USA
Short Talk: Anti-Semaphorin 4D Therapeutic Antibody Recruits Activated Tumor Infiltrating Leukocytes and Reverses Tumor Growth

Rupali Das, Children's Hospital of Philadelphia, USA
Short Talk: Cancer Immunotherapeutic Potential of NKTT320, a Novel Human iNKT Cell Activating Monoclonal Antibody

8:00—11:00 AM
Genomic, Metabolomic and Proteomic Advances in Cancer Immunotherapy

Van Horne Ballroom A/B
* Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Neo-Antigens in Human Cancer

Lélia Delamarre, Genentech, Inc., USA
Short Talk: Predictive Identification of Immunogenic Mutations in Cancer

Matthew M. Gubin, Washington University in St. Louis, USA
Short Talk: Checkpoint Blockade Cancer Therapy Targets Tumor-Specific Mutant Antigens

Jonathan D. Powell, Johns Hopkins University School of Medicine, USA
Targeting mTOR and Metabolism to Enhance Anti-Tumor Immunotherapy

Antony Rosen, Johns Hopkins University School of Medicine, USA
Cancer and the Autoimmune Rheumatic Diseases: Mechanistic Insights

9:20—9:40 AM
Coffee Break

Van Horne Foyer
11:15 AM—1:00 PM
Poster Setup

Mezzanine 2
1:00—10:00 PM
Poster Viewing

Mezzanine 2
11:15 AM—5:00 PM
On Own for Lunch

4:30—5:00 PM
Coffee Available

Van Horne Foyer
5:00—7:00 PM
Alternative Tumor Targeting Approaches

Van Horne Ballroom C
* Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Limits of Tumor Targeting in Immunotherapy: Theory and Experiment

Bryan A. Irving, CytomX Therapeutics, Inc, USA
Probodies Empower a New Generation of Antibody Immunotherapies

Peter Molloy, Immunocore Ltd., UK
ImmTACs: Bi-specific TCR-based Reagents for Targeted Cancer Immunotherapy

Heather A. Huet, Novartis Institutes for Biomedical Research, USA
Short Talk: Targeting Ovarian Cancer with ESK1, a Glycoengineered TCR-Mimic Antibody Directed Against the Intracellular Transcription Factor WT1 with Enhanced ADCC Killing

5:00—7:00 PM
Human Immunology: Functional Insights for Cancer Immunotherapy

Van Horne Ballroom A/B
Eliane Piaggio, Immunity and Cancer - Institut Curie / INSERM, France
Short Talk: Lymph Node Invasion by Tumor Cells Modifies the Distribution and Phenotype of Dendritic and T Cell Subsets in Breast Cancer Patients

* Pia Kvistborg, Netherlands Cancer Institute, Netherlands
Effects of Checkpoint Targeting on the Tumor-Specific T Cell Response

Steven M. Larson, Memorial Sloan-Kettering Cancer Center, USA
Radioimmunotherapy (RIT) of Solid Tumors

Jay A. Berzofsky, NCI, National Institutes of Health, USA
Talk Title to be Announced

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
7:30—10:00 PM
Poster Session 2

Mezzanine 2

WEDNESDAY, FEBRUARY 11

7:00—8:00 AM
Breakfast

Mezzanine 2
8:00—11:15 AM
Clinical Progress with Bispecific Antibodies for Dual Blockade

Van Horne Ballroom C
* Mark X. Sliwkowski, Genentech, Inc., USA

Gabriele Schaefer, Genentech, Inc., USA
MEHD7495A, a Dual-Action-Antibody Targeting HER3 and EGFR: Preclinical and Clinical Evaluation

Alexey Lugovskoy, Merrimack Pharmaceuticals Inc., USA
MM-141: Dual Antibody Inhibitor of IGF-1R and ErbB3 Targeting Redundancies and Adaptation in Oncogenic Signaling

Oliver Krieter, , Germany
Clinical Progress with RG7221 (RO5520985), a Bi-Specific Human IgG1 Antibody Against Ang-2 and VEGF-A for the Treatment of Cancer

Tariq Ghayur, AbbVie Inc., USA
Preclinical and Clinical Progress of Dual-Variable-Domain-Ig (DVD-IgTM) Molecules for Autoimmune Indications

Mathias Locher, Covagen AG, Switzerland
Short Talk: COVA322: A Clinical Stage TNF/IL-17A Bispecific FynomAb for the Treatment of Inflammatory Diseases

Miho Funaki, Chugai Pharmaceutical Co. Ltd., Japan
Short Talk: Novel Bispecific Antibody against Activated Factor IXa and Factor X (ACE910) for Treatment of Hemophilia A

8:00—11:00 AM
Influence of Conventional Therapies on the Immune System

Van Horne Ballroom A/B
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Immune Responses to Immune Checkpoint Therapies

* Ira Mellman, Genentech, Inc., USA
Targeted Molecular Therapy Takes on Immunotherapy

Dan G. Duda, Harvard Medical School, Massachusetts General Hospital, USA
Short Talk: Rationally Combining Antiangiogenic Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma

Daniel E. Speiser, Ludwig Center, University of Lausanne, Switzerland
Multidisciplinary Approaches to Target both Cancer Cell-Internal and -External Disease Mechanisms

Roopa Srinivasan, GlaxoSmithKline, USA
Effects of Targeted Therapies on Tumor and Immune System

9:20—9:40 AM
Coffee Break

Van Horne Foyer
11:15 AM—1:00 PM
Poster Setup

Mezzanine 2
1:00—10:00 PM
Poster Viewing

Mezzanine 2
11:15 AM—5:00 PM
On Own for Lunch

4:30—5:00 PM
Coffee Available

Van Horne Foyer
5:00—7:00 PM
Antibodies for Infectious Diseases

Van Horne Ballroom C
Gerald B. Pier, Harvard Medical School, USA
Anti-Microbial Antibody Therapy

* Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Broadly Neutralizing Anti-Viral Antibodies

Yaoxing Huang, Aaron Diamond AIDS Research Center, USA
Passive Immunization Approaches to HIV Prevention

Ian Huh, California State University, Fresno, USA
Short Talk: Neutralization of Listeria monocytogenes by Single Domain Antibodies

5:00—7:15 PM
Advances in Therapeutic Platforms: Vaccines, Cellular Therapies and Immune Modulators

Van Horne Ballroom A/B
Laurence J. N. Cooper, ZIOPHARM Oncology, Inc., USA
Genetic Modification of T Cells Using Sleeping Beauty System for Human Applications

* Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Synergy of Therapeutic Vaccination Against HPV16 Oncogenic Proteins and Conventional Chemotherapeutics

Khaled H. Barakat, University of Alberta, Canada
Short Talk: Rational Design of Small Molecule Immune Checkpoints' Inhibitors

Jolanda de Vries, NCMLS, Radboud University Medical Center, Netherlands
Natural Dendritic Cell Vaccine: A More Powerful Next Generation?

Sandeep T. Koshy, Harvard University, USA
Short Talk: Tumor Immunomodulation Using an Injectable Biomaterials Scaffold

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
7:30—10:00 PM
Poster Session 3

Mezzanine 2

THURSDAY, FEBRUARY 12

7:00—8:00 AM
Breakfast

Mezzanine 2
8:00—11:15 AM
Engineering Immunological Scaffolds for Improved Delivery and Disposition

Van Horne Ballroom C
* Serge Muyldermans, Vrije Universiteit Brussel, Belgium
Nanobodies for Alternative Delivery Routes

Kristen M. Picha, Centyrex, Janssen Research & Development, USA
Novel Delivery Strategies for Alternative Scaffolds

Tomoyuki Igawa, Chugai Pharmabody Research, Singapore
Engineered pH-Dependent Binding Antibody for Efficient Elimination of Soluble Antigen from Plasma

* Michael Stumpp, Molecular Partners, Switzerland
DARPins for Ocular Diseases and Beyond

Yu-Ju Gloria Meng, Genentech, Inc., USA
Short Talk: Intravitreally Injected Bispecific F(ab’)2 Had Similar Intraocular Concentrations and Reduced Circulating Concentrations Compared to IgG

Jens Niewoehner, Roche Pharma Research and Early Development, Germany
Short Talk: Engineering a Brain Shuttle for Therapeutic Protein Delivery

8:00—11:00 AM
Methodological Advances in Clinical and Biomarker Investigation

Van Horne Ballroom A/B
Ugur Sahin, BioNTech AG, Germany
Individualized Cancer Immunotherapy

James P. Allison, University of Texas MD Anderson Cancer Center, USA
Investigating Emerging Checkpoint Targets and their Modulators

Taha Merghoub, Memorial Sloan-Kettering Cancer Center, USA
Genetic Basis Underlying Clinical Response to Checkpoint Blockade

Nir Hacohen, Massachusetts General Hospital, USA
Genetic and Genomic Analysis of Tumor Immunity

9:20—9:40 AM
Coffee Break

Van Horne Foyer
11:15 AM—2:30 PM
On Own for Lunch

2:30—4:30 PM
Workshop 2: New Library Design and Screening Technologies

Van Horne Ballroom C
* Pablo Umaña, Roche Innovation Center Zürich, Switzerland

* Catherine Hutchings, Heptares Therapeutics, UK

Belay Gessesse Bezabeh, University of Tokyo, Japan
Cell-Free Synthesis of the Human Chemokine G-Protein Coupled Receptor for Future Antibody Screening

Ling Chen, Guangzhou Institute of Biomedicine and Health, CAS, China
Rapid Generation of Antiviral Antibodies for Human Application in Rhesus macaques in Responding to Emerging Influenza and Virulent Viral Infections

Amandeep K. Gakhal, Sutro Biopharma, USA
Discovery and Characterization of Therapeutic Antibodies for an Engineered Cell-Free Expression System

Ben Hoffstrom, Fred Hutchinson Cancer Research Center, USA
High-Throughput Screening for Monoclonal Antibodies to Multiplexed Antigens

Michael-Paul Robinson, Cornell University, USA
Production of Full-length Antibodies in the Cytoplasm of E. coli

Imre Kacskovics, ImmunoGenes Ltd, Hungary
Transgenic Animals that Overexpress the Neonatal Fc Receptor (FcRn) Have Improved Antibody Generation

2:30—4:30 PM
Workshop 2: Re-Visiting Past Approaches to Cancer Immunotherapy - Lessons from Failures to Enable Future Successes

Van Horne Ballroom A/B
* Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands

* James P. Allison, University of Texas MD Anderson Cancer Center, USA

Jason R. Baird, Earle A. Chiles Research Institute, USA
Radiation Therapy Combined with Novel Oligonucleotides Targeting STING in Tumor Stroma Result in Cure of Established Tumors

Hélène Salmon, Icahn School of Medicine at Mount Sinai, USA
In situ Activation and Expansion of CD103+ DCs at the Tumor Site Dramatically Increase Melanoma Response to BRAF and PDL1 Inhibition Therapy

Katherine E. Lewis, Bristol-Myers Squibb Company, USA
Dual Targeting of PD-1 and LAG-3 Demonstrates Superior Efficacy to Blocking Either PD-1 or LAG-3 Alone in Pre-Clinical Solid and Hematological Tumor Models

Carola H. Ries, Roche Innovation Center Munich, Germany
Targeting Tumor-Associated Macrophages with Anti-CSF1R Antibody in Combination with Chemotherapy

Ryan Rountree, Nurix, Inc., USA
Poxvirus-Based Active Immunotherapy Induces PD-L1 Expression in the Tumor Microenvironment and Results in Dramatic Anti-Tumor Efficacy in Combination with PD-1 Axis Blockade

Peter R. Rhode, Altor BioScience Corp., USA
Enhanced Efficacy of Immune Checkpoint Blockers and Therapeutic Antibodies in Combination with an IL-15-Based Superagonist Complex in Various Mouse Tumor Models

4:30—5:00 PM
Coffee Available

Van Horne Foyer
5:00—6:45 PM
Addressing Difficult Targets - GPCRs and Ion Channels

Van Horne Ballroom C
* Catherine Hutchings, Heptares Therapeutics, UK
Using Stabilized Receptors as Antigens to Generate Therapeutic Antibodies to GPCR Targets

Vaughn V. Smider, The Scripps Research Institute, USA
Ultralong CDR3s for Targeting Ion Channels and GPCRs

Caroline Colley, MedImmune, UK
Identifying Antibodies to GPCRs and Ion-Channels

5:00—6:45 PM
Scientific and Clinical Progress in Combination Therapy

Van Horne Ballroom A/B
* Axel Hoos, GlaxoSmithKline, USA

F. Stephen Hodi, Dana-Farber Cancer Institute, USA
Immunological Scaffolds as Therapeutics: A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients

Cassian Yee, University of Texas MD Anderson Cancer Center, USA
Adoptive T Cell Therapy: A Personalized Approach for Common Cancers

Silvia C. Formenti, New York University Langone Medical Center, USA
Combination Therapy Potential of Radiation Therapy as in-situ Vaccination

6:45—7:15 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Van Horne Ballroom C
6:45—7:15 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Ballroom A/B
7:15—8:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Mezzanine 2
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Mezzanine 2

FRIDAY, FEBRUARY 13

 
Departure


*Session Chair †Invited, not yet responded.


We gratefully acknowledge support for this conference from:


Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Genentech, Inc. ImmunoGen, Inc.
Mersana Therapeutics OncoMed Pharmaceuticals, Inc.
Pfizer Inc. Regeneron Pharmaceuticals, Inc.
Shire Human Genetic Therapies
 

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI116024-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



AbbVie Inc.


Amgen Inc.


BioNTech RNA Pharmaceuticals GmbH


Celldex Therapeutics, Inc.


Genentech, Inc.


Heptares Therapeutics Ltd


Janssen R&D: Pharmaceutical Companies of Johnson & Johnson


MedImmune


Merrimack Pharmaceuticals


Molecular Partners AG


Regeneron Pharmaceuticals, Inc.


Roche Diagnostics GmbH

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179